• PDF / 169,827 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 83 Downloads / 212 Views

DOWNLOAD

REPORT

---

1 S

Doxorubicin-liposomal Squamous cell carcinoma of the mouth and squamous cell carcinoma of the tongue: 2 case reports

In a retrospective cohort study involving 69 women treated with doxorubicin liposomal from 1991 to 2016, 2 women [ages not stated] were described, of whom, one woman developed squamous cell carcinoma (SCC) of the mouth and the other woman developed SCC of the tongue during treatment with doxorubicin liposomal for recurrent epithelial ovarian carcinoma (rEOC) [routes and exact dosages not stated]. Both the women, who had rEOC, had received unspecified platinum and taxane chemotherapy. Thereafter, both the women started receiving doxorubicin liposomal [Pegylated liposomal doxorubicin]. Of these 2 women, one woman who was positive for breast cancer type-1 (BRCA1) mutation, developed stage-I SCC of the mouth after 38 cycles of doxorubicin liposomal (after receiving a cumulative dose of 1056 mg/m2); while the another woman developed stage-I squamous cell carcinoma of the tongue following 16 cycles of doxorubicin liposomal (after receiving a cumulative dose of 640 mg/m2). The SCCs were considered to be doxorubicin liposomal-related toxicities [durations of treatments to reactions onsets not stated]. The woman, who developed SCC of the mouth, however exhibited a complete response to doxorubicin liposomal treatment and there was no evidence of disease before development of the oral squamous cell carcinoma; while the other woman exhibited a recurrence of EOC, and she eventually died due to rEOC before receiving any treatment for the tongue cancer [outcomes of the reactions not stated]. Chambers LM, et al. Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer. Gynecologic Oncology 158: 803500066 309-315, No. 2, Aug 2020. Available from: URL: http://doi.org/10.1016/j.ygyno.2020.04.708

0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Sep 2020 No. 1820